An in vitro selected binding protein (affibody) shows conformation-dependent recognition of the respiratory syncytial virus (RSV) G protein.

Using phage-display technology, a novel binding protein (Z-affibody) showing selective binding to the RSV (Long strain) G protein was selected from a combinatorial library of a small alpha-helical protein domain (Z), derived from staphylococcal protein A (SPA). Biopanning of the Z-library against a recombinant fusion protein comprising amino acids 130-230 of the G protein from RSV-subgroup A, resulted in the selection of a Z-affibody (Z(RSV1)) which showed G protein specific binding. Using biosensor technology, the affinity (K(D)) between Z(RSV1) and the recombinant protein was determined to be in the micromolar range (10(-6) M). Interestingly, the Z(RSV1) affibody was demonstrated to also recognize the partially (54%) homologous G protein of RSV subgroup B with similar affinity. Using different recombinant RSV G protein derived fragments, the binding was found to be dependent on the presence of the cysteinyl residues proposed to be involved in the formation of an intramolecular disulfide-constrained loop structure, indicating a conformation-dependent binding. Results from epitope mapping studies, employing a panel of monoclonal antibodies directed to different RSV G protein subfragments, suggest that the Z(RSV1) affibody binding site is located within the region of amino acids 164-186 of the G protein. This region contains a 13 amino acid residue sequence which is totally conserved between subgroups A and B of RSV and extends into the cystein loop region (amino acids 173-186). The potential use of the RSV G protein-specific Z(RSV1) affibody in diagnostic and therapeutic applications is discussed.

[1]  M. Uhlén,et al.  Hydrophobicity engineering to increase solubility and stability of a recombinant protein from respiratory syncytial virus. , 1995, European journal of biochemistry.

[2]  P. Cane,et al.  Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein. , 1997, The Journal of general virology.

[3]  Tristan J. Vaughan,et al.  Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library , 1996, Nature Biotechnology.

[4]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[5]  H R Hoogenboom,et al.  Antibody phage display technology and its applications. , 1998, Immunotechnology : an international journal of immunological engineering.

[6]  Geraldine Taylor,et al.  Reshaping a Human Monoclonal Antibody to Inhibit Human Respiratory Syncytial Virus Infection in Vivo , 1991, Bio/Technology.

[7]  M. Ptashne,et al.  Gene regulation at the right operator (OR) bacteriophage lambda. I. OR3 and autogenous negative control by repressor. , 1980, Journal of molecular biology.

[8]  M. Uhlén,et al.  Analysis and use of the serum albumin binding domains of streptococcal protein G , 1988, Journal of molecular recognition : JMR.

[9]  M. Uhlén,et al.  A synthetic IgG-binding domain based on staphylococcal protein A. , 1987, Protein engineering.

[10]  M. Uhlén,et al.  Single–Step Recovery of a Secreted Recombinant Protein by Expanded Bed Adsorption , 1994, Bio/Technology.

[11]  M. Uhlén,et al.  Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain , 1997, Nature Biotechnology.

[12]  J. Deisenhofer.  Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[13]  U. Rüther.  pUR 250 allows rapid chemical sequencing of both DNA strands of its inserts. , 1982, Nucleic acids research.

[14]  B. Moss,et al.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Uhlén,et al.  Flow cytometric quantification of surface-displayed recombinant receptors on staphylococci. , 1997, BioTechniques.

[16]  T. Nguyen,et al.  The serum albumin-binding region of streptococcal protein G (BB) potentiates the immunogenicity of the G130-230 RSV-A protein. , 1999, Vaccine.

[17]  M. Uhlén,et al.  A dual expression system for the generation, analysis and purification of antibodies to a repeated sequence of the Plasmodium falciparum antigen Pf155/RESA. , 1989, Journal of immunological methods.

[18]  M. Uhlén,et al.  Direct solid phase sequencing of genomic and plasmid DNA using magnetic beads as solid support. , 1989, Nucleic acids research.

[19]  A Tramontano,et al.  Identification of biologically active peptides using random libraries displayed on phage. , 1995, Current opinion in biotechnology.

[20]  E. Norrby,et al.  Two distinct subtypes of human respiratory syncytial virus. , 1985, The Journal of general virology.

[21]  M. Uhlén,et al.  Competitive elution of protein A fusion proteins allows specific recovery under mild conditions. , 1994, European journal of biochemistry.

[22]  M. Uhlén,et al.  Production of a thermostable DNA polymerase by site-specific cleavage of a heat-eluted affinity fusion protein. , 1997, Protein expression and purification.

[23]  R. Karron,et al.  An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. , 1994, Virus research.

[24]  M. Trudel,et al.  Involvement of the complement system in the protection of mice from challenge with respiratory syncytial virus Long strain following passive immunization with monoclonal antibody 18A2B2 , 1996, Vaccine.

[25]  S. Josephson,et al.  Secretion of peptides from E. coli: a production system for the pharmaceutical industry , 1988 .

[26]  I. S. Dunn.  Phase display of proteins , 1996 .

[27]  C. Milstein,et al.  Derivation of specific antibody‐producing tissue culture and tumor lines by cell fusion , 1976, European journal of immunology.

[28]  E. Norrby,et al.  Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B. , 1987, The Journal of general virology.

[29]  R. Chanock,et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. , 1969, American journal of epidemiology.

[30]  M. Uhlén,et al.  Scaffolds for engineering novel binding sites in proteins. , 1997, Current opinion in structural biology.

[31]  P. Tournier,et al.  Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. , 1997, The Journal of infectious diseases.

[32]  B. Graham,et al.  Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. , 1997, Vaccine.

[33]  R. Lerner,et al.  A subgroup-specific antigenic site in the G protein of respiratory syncytial virus forms a disulfide-bonded loop , 1990, Journal of virology.

[34]  M. Uhlén,et al.  A combinatorial library of an α-helical bacterial receptor domain , 1995 .

[35]  M. Uhlén,et al.  Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. , 1997, Virology.

[36]  G. Montelione,et al.  High-level production of uniformly 15N-and 13C-enriched fusion proteins in Escherichia coli , 1996 .

[37]  R. Chanock,et al.  Isolation of a second recombinant human respiratory syncytial virus monoclonal antibody fragment (Fab RSVF2-5) that exhibits therapeutic efficacy in vivo. , 1998, The Journal of infectious diseases.

[38]  P. Collins,et al.  The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  H. Binz,et al.  Protective immunity against respiratory syncytial virus in early life after murine maternal or neonatal vaccination with the recombinant G fusion protein BBG2Na. , 1997, The Journal of infectious diseases.

[40]  E. Walsh,et al.  Induction of local and systemic immunity against human respiratory syncytial virus using a chimeric FG glycoprotein and cholera toxin B subunit. , 1994, Vaccine.

[41]  M. Hansson,et al.  Hydrophobicity engineering to facilitate surface display of heterologous gene products on Staphylococcus xylosus. , 1995, Journal of biotechnology.

[42]  W. Marasco.  Intracellular antibodies (intrabodies) as research reagents and therapeutic molecules for gene therapy. , 1995, Immunotechnology : an international journal of immunological engineering.

[43]  J. Dopazo,et al.  Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants. , 1997, The Journal of general virology.

[44]  D R Burton,et al.  Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[45]  T. Clackson,et al.  In vitro selection from protein and peptide libraries. , 1994, Trends in biotechnology.

[46]  M. Uhlén,et al.  Mutational analysis of the interaction between staphylococcal protein A and human IgG1. , 1993, Protein engineering.

[47]  Mathias Uhlén,et al.  Multiple affinity domains for the detection, purification and immobilization of recombinant proteins , 1996, Journal of molecular recognition : JMR.